Coronavirus: U.K. trial to test combining Pfizer, AstraZeneca vaccines in 2-shot regimen

Britain on Thursday launched a trial to assess the immune responses generated if doses of the COVID-19 vaccines from Pfizer Inc. and AstraZeneca Plc are combined in a two-shot schedule. Matthew Snape, an Oxford vaccinologist who is leading the trial, said initial results could inform vaccine deployment in the second half of the year.

• AztraZeneca’s vaccine effective in elderly and against U.K. variant, new reports suggest
• Parkinson’s disease patients should be prioritized for COVID-19 vaccines: experts
• Vaccine mix-and-match: U.K. to study efficacy of combining shots